Dalia Barsyte-Lovejoy

Nov 23, 2024 | nature.com | Serah Kimani |Laurent Hoffer |Stuart Green |Dalia Barsyte-Lovejoy |Vijayaratnam Santhakumar |Suzanne Ackloo | +5 more

AbstractProteolysis-targeting chimeras (PROTACs) have been explored for the degradation of drug targets for more than two decades. However, only a handful of E3 ligase substrate receptors have been efficiently used. Downregulation and mutation of these receptors would reduce the effectiveness of such PROTACs. We recently developed potent ligands for DCAF1, a substrate receptor of EDVP and CUL4 E3 ligases.